Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials have?
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials has 361 citations in the OpenAlex counts ScholarIQ stores.
When was Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials published?
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials has 2018 year in the ScholarIQ index.
What is the open-access status of Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials?
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials has closed oa status in the ScholarIQ index.
What is the DOI of Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials?
The DOI for Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials is on the source record.
What is the PMID of Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials?
The PMID for Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials is on the source record.
What is the OpenAlex record for Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials?
The OpenAlex for Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials is on the source record.